Skip to main content

Hemodialysis

Nephrology
4
Pipeline Programs
12
Companies
13
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
3
0
Early DiscoveryClinical DevelopmentMarket

Nephrology is a $36.6B mature market dominated by cardiometabolic crossover drugs with limited pure renal innovation.

$36.6B marketMature→ Stable30 products15 companies

Key Trends

  • GLP-1 agonists and SGLT2 inhibitors dominate (69% of spending) due to dual cardio-renal benefits
  • Patent cliffs approaching 2026-2030 create generic conversion risk for blockbuster franchises
  • Pipeline activity remains robust (2,785 trials) but concentrated in early-phase basic research

Career Verdict

Nephrology offers stable employment in commercial and medical affairs roles, but limited growth upside due to mature blockbuster dependency and declining pure renal research focus.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1OZEMPICStable
$9.2B
Novo Nordisk·Peak12.4yr
#2JARDIANCEStable
$8.8B
Boehringer Ingelheim·Peak8.6yr
#3TRULICITYStable
$7.4B
Eli Lilly and Company·Peak
#4FARXIGAStable
$4.3B
AstraZeneca·Peak15.4yr

Drug Class Breakdown

Glucagon-like Peptide-1 (GLP-1) Agonists
$16.6B(45%)

cardiometabolic dominance

Sodium-Glucose Transporter 2 Inhibitors
$8.8B(24%)

cardioprotective expansion

SGLT2 Inhibitors (dapagliflozin class)
$4.3B(12%)

heart failure crossover

Adrenergic Beta3-Agonists
$3.0B(8%)

overactive bladder niche

Dipeptidyl Peptidase 4 Inhibitors
$1.3B(4%)

declining relevance

Career Outlook

Stable

Nephrology careers are stable but not expanding; the field is supported by blockbuster drugs (GLP-1s, SGLT2i) that face patent cliffs between 2026–2041, creating near-term employment security but long-term uncertainty. Commercial and medical affairs roles dominate hiring, while R&D investment is limited to niche mechanisms (complement inhibition, gene therapy). Career progression depends on specialization in medtech, diagnostics, or orphan nephrology rather than traditional pharma blockbuster development.

Breaking In

Target medtech platforms (Outset, Fresenius) or biotech innovators (Vertex, Calyxo) over traditional pharma; nephrology offers job stability and clinical depth but limited growth trajectory in pure pharmaceutical roles.

For Experienced Professionals

Leverage cardiometabolic expertise to span diabetes, CKD, and HF franchises; position for transition to orphan nephrology (ADPKD, FSGS, IgA) where innovation and valuation multiples are highest.

In-Demand Skills

Renal endpoints and biomarkers (eGFR, albuminuria)Cardio-renal crossover knowledge (diabetes + CKD + HF)Medtech systems expertise (dialysis, transplantation platforms)Medical affairs and key opinion leader management

Best For

Medical Science Liaison (renal specialists)Commercial Manager (established nephro franchise)Clinical Development Manager (rare kidney disease)Real-world evidence analyst (CKD outcomes)

Hiring Landscape

$108K–$330K

Nephrology hiring is concentrated in commercial roles (58 positions, $108K avg) and medical affairs (12 positions, $330K avg), reflecting mature market dynamics. Top hiring companies are innovative platforms (Vertex: 41 jobs) and medtech (Outset: 21 jobs), not traditional pharma. Salary compression in commercial roles suggests commoditization.

124
Open Roles
5
Companies Hiring
4
Departments

Top Hiring Companies

Vertex Pharmaceuticals
41Growing
Outset Medical
21Growing
Calyxo
20Growing
Biogen
8Stable
AstraZeneca
5Stable

By Department

Commercial(47%)
$108K
Medical Affairs(10%)
$330K
Clinical Excellence(6%)
$140K
Quality Assurance(4%)
$201K

Hiring favors medtech and biotech platforms over traditional pharma; medical affairs offers premium compensation but limited volume; commercial roles are abundant but underpaid relative to other therapeutic areas.

Competitive Landscape

12 companies ranked by most advanced pipeline stage

Kissei Pharmaceutical
Kissei PharmaceuticalJapan - Matsumoto City
2 programs
2
PA21Phase 31 trial
PA21Phase 31 trial
Active Trials
NCT01850602Completed213Est. Dec 2013
NCT01850641Completed35Est. Dec 2013
Innovation Pharmaceuticals
1 program
1
Lanthanum CarbonatePhase 31 trial
Active Trials
NCT01578200Completed2,309Est. Mar 2019
Sunshine Biopharma
Sunshine BiopharmaQC - Varennes
1 program
1
HEC53856Phase 11 trial
Active Trials
NCT04925674Completed60Est. Oct 2022
Baxter International
3 programs
GamCath® central venous catheterN/A1 trial
Gambro HD-C4 Small DialyzerN/A1 trial
Short daily dialysis for 2 weeksN/A1 trial
Active Trials
NCT00621114Completed69Est. Jul 2009
NCT00579202Completed24Est. Nov 2007
NCT01975025Completed17Est. Aug 2014
Baxter
BaxterCosta Rica - Cartago
3 programs
GamCath® central venous catheterN/A
Gambro HD-C4 Small DialyzerN/A
Short daily dialysis for 2 weeksN/A
Vantive
VantiveIL - Deerfield
2 programs
GamCath® central venous catheterN/A
Gambro HD-C4 Small DialyzerN/A
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
1 program
Estimating and Predicting Hemodynamic Changes During HemodialysisN/A1 trial
Active Trials
NCT01700465Completed241Est. Dec 2016
Merit Medical
Merit MedicalSOUTH JORDAN, UT
1 program
HeRO Vascular Access DeviceN/A1 trial
Active Trials
NCT00889564Completed38Est. Mar 2007
Bilim Pharmaceuticals
Bilim PharmaceuticalsTurkey - Istanbul
1 program
Lavender oilN/A1 trial
Active Trials
NCT04666363Completed36Est. May 2021
Martin Pharmaceuticals
1 program
praebiotic inner fermentable pea fibresN/A1 trial
Active Trials
NCT07544797Not Yet Recruiting72Est. Dec 2028
Regeneron
RegeneronTARRYTOWN, NY
1 program
Alirocumab 150 MG/ML [Praluent]PHASE_31 trial
Active Trials
NCT03480568Unknown20Est. Dec 2020
Chugai Pharma
Chugai PharmaJapan - Tokyo
1 program
Sevelamer HClPHASE_41 trial
Active Trials
NCT01755078Completed166Est. Jun 2009

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Chugai PharmaSevelamer HCl
RegeneronAlirocumab 150 MG/ML [Praluent]
Kissei PharmaceuticalPA21
Kissei PharmaceuticalPA21
Innovation PharmaceuticalsLanthanum Carbonate
Sunshine BiopharmaHEC53856
Martin Pharmaceuticalspraebiotic inner fermentable pea fibres
Bilim PharmaceuticalsLavender oil
Baxter InternationalShort daily dialysis for 2 weeks
Colorado TherapeuticsEstimating and Predicting Hemodynamic Changes During Hemodialysis
Baxter InternationalGambro HD-C4 Small Dialyzer
Baxter InternationalGamCath® central venous catheter
Merit MedicalHeRO Vascular Access Device

Clinical Trials (13)

Total enrollment: 3,300 patients across 13 trials

NCT01755078Chugai PharmaSevelamer HCl

Long Term Evaluation of Sevelamer HCl vs. Calcium-based Phosphate Binder in the Treatment of Hyperphosphatemia in Hemodialysis Patients

Start: Jun 2007Est. completion: Jun 2009166 patients
Phase 4Completed
NCT03480568RegeneronAlirocumab 150 MG/ML [Praluent]

Alirocumab in Patients on a Stable Dialysis Regimen

Start: May 2018Est. completion: Dec 202020 patients
Phase 3Unknown
NCT01850641Kissei PharmaceuticalPA21

A Phase III Study of PA21 With Calcium Carbonate in Hemodialysis Patients With Hyperphosphatemia

Start: Apr 2013Est. completion: Dec 201335 patients
Phase 3Completed
NCT01850602Kissei PharmaceuticalPA21

A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia

Start: Apr 2013Est. completion: Dec 2013213 patients
Phase 3Completed
NCT01578200Innovation PharmaceuticalsLanthanum Carbonate

Outcome Study of Lanthanum Carbonate Compared With Calcium Carbonate in Hemodialysis Patients : Landmark Study

Start: Dec 2011Est. completion: Mar 20192,309 patients
Phase 3Completed
NCT04925674Sunshine BiopharmaHEC53856

Study of HEC53856 in Patients With Subjects With End-Stage Renal Disease Receiving Dialysis.

Start: Sep 2021Est. completion: Oct 202260 patients
Phase 1Completed
NCT07544797Martin Pharmaceuticalspraebiotic inner fermentable pea fibres

Pea Fibre in Hemodialysis

Start: May 2026Est. completion: Dec 202872 patients
N/ANot Yet Recruiting
NCT04666363Bilim PharmaceuticalsLavender oil

Inhaled Lavender Applied at Hemodialysis Patients and Effect on Pain, Comfort, and Anxiety

Start: Feb 2021Est. completion: May 202136 patients
N/ACompleted
NCT01975025Baxter InternationalShort daily dialysis for 2 weeks

Hemodialysis Frequency and the Calcification Propensity of Serum

Start: Jun 2014Est. completion: Aug 201417 patients
N/ACompleted
NCT01700465Colorado TherapeuticsEstimating and Predicting Hemodynamic Changes During Hemodialysis

Estimating and Predicting Hemodynamic Changes During Hemodialysis

Start: Sep 2012Est. completion: Dec 2016241 patients
N/ACompleted
NCT00579202Baxter InternationalGambro HD-C4 Small Dialyzer

Ease of Use Study for the Gambro Polyflux HD-C4 Small Dialyzer

Start: Oct 2007Est. completion: Nov 200724 patients
N/ACompleted
NCT00621114Baxter InternationalGamCath® central venous catheter

Ex Vivo Microbiological Assessment of an Anti-biofilm Catheter in Acute Dialysis Application

Start: Aug 2007Est. completion: Jul 200969 patients
N/ACompleted
NCT00889564Merit MedicalHeRO Vascular Access Device

HeRO Vascular Access Device Bacteremia Study

Start: Mar 2006Est. completion: Mar 200738 patients
N/ACompleted

Related Jobs in Nephrology

Farm Operations Technician

eGenesiseGenesis
Greater Madison, WI Area
3d ago

Sr. Research and Development Technician - Pleasanton, CA

CalyxoCalyxo
Pleasanton, CA
4d ago
$85K - $96K/yr

Chicago South based Clinical Specialist - Remote, USA

CalyxoCalyxo
Remote
5d ago
$100K - $140K/yr

Platform Engineer

AxiomAxiom
SF Global HQ
5d ago

Wilmington, NC based Territory Sales Manager - Remote, USA

CalyxoCalyxo
Remote
6d ago
From $120K/yr

Statistical Programmer Contractor

ProKidneyProKidney
6d ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs, potential near-term approvals
12 companies competing in this space

Related Indications

Chronic Kidney Disease(220)End Stage Renal Disease(203)Renal Impairment(142)Kidney Transplantation(136)Chronic Kidney Diseases(71)Renal Insufficiency(66)Acute Kidney Injury(66)Kidney Diseases(46)Renal Transplantation(45)Kidney Transplant(41)

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.